How GLP-1 Weight Loss Drug Economics Reshape US Food Industry
GLP-1 weight loss drug economics are driving significant changes in the US food industry. These drugs influence patient dietary habits, leading to shifts in agricultural demand and food manufacturing. Understanding these economic impacts helps clinicians…
Ozempic Face: Muscle Loss & Body Composition Facts
GLP-1 weight loss therapy can lead to noticeable changes in facial volume, often called Ozempic face. This effect results from rapid fat loss impacting body composition. Understanding these changes helps clinicians manage patient expectations effectively.
AM News Update: March 16, 2026
Cannabis use by older adults is increasingly common and raises important questions about mental decline risks. This update reviews recent findings on cognitive effects and safety concerns. Understanding cannabis use by older adults helps guide clinical…
Cannabinoid Clinical Trials: GLP-1 Receptors and Mental Health
The GLP-1 receptor agonists mental health study reveals potential protective effects against schizophrenia and other psychiatric conditions. This Mendelian randomization analysis uses genetic proxies to explore causal relationships. Findings suggest…
CED Cannabis Research Digest — February 27, 2026
The cannabis medicine research digest for February 27, 2026, highlights key peer-reviewed studies scored for clinical relevance. This weekly digest provides a curated summary of cannabis research to inform patient care. Stay updated with the latest…
Endocannabinoid System & GLP-1 Mental Health Evidence
GLP-1 receptor agonists mental health evidence suggests these drugs may influence psychiatric disorder risks. Genetic studies indicate potential benefits for schizophrenia. Patients should discuss mental health implications with clinicians.
Endocannabinoid System Research: GLP-1 and Mental Health Insights
GLP-1 receptor agonists mental health effects were examined using Mendelian randomization to assess their impact on common mental illnesses. This genetic study suggests a potential causal link between GLP-1 receptor agonists and reduced schizophrenia…